Loading...
XASXPYC
Market cap421mUSD
Dec 24, Last price  
1.40AUD
1D
0.00%
1Q
866.67%
Jan 2017
6,039.91%
IPO
622.63%
Name

PYC Therapeutics Ltd

Chart & Performance

D1W1MN
XASX:PYC chart
P/E
—
P/S
29.61
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
7.05%
Rev. gr., 5y
-40.58%
Revenues
22m
+39.56%
52,5560275,38590,7521,274,942596,2562,358,5321,918,368711,891739,391829,1191,0762,762,73348,46002,395,7063,074,36816,042,82115,806,25622,059,314
Net income
-38m
L+65.54%
-1,587,323-3,991,475-3,888,673-4,483,938-4,490,920-4,572,825-3,605,169-3,904,524-3,439,624-3,257,695-2,991,479-3,978,672-1,950,837-7,433,997-4,079,767-6,822,215-17,767,586-13,863,159-22,788,985-37,725,411
CFO
-39m
L+58.01%
00000000-2,315,203-3,200,291-2,481,246-3,166,729-1,883,136-6,707,273-5,125,413-5,748,405-11,791,314-21,782,280-24,421,686-38,588,501
Earnings
Feb 26, 2025

Profile

PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of drug solutions in the areas of ribonucleic acid therapeutics in Australia. The company's preclinical development programs include VP-001, drug program for retinitis pigmentosa type 11; and PYC-001, a drug program for the treatment of autosomal dominant optic atrophy. It also focuses on the development of programs for kidney, retinal, and central nervous system diseases. PYC Therapeutics Limited has academic-industry collaborations with Murdoch University to support drug discovery and development efforts in the field of neurodegenerative disorders, including Motor Neurone Disease. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.
URL
https://pyctx.com/
IPO date
Mar 30, 2005
Employees
23
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
22,059
39.56%
15,806
-1.47%
16,043
421.83%
Cost of revenue
60,917
39,163
30,208
Unusual Expense (Income)
NOPBT
(38,857)
(23,357)
(14,165)
NOPBT Margin
Operating Taxes
(17,559)
(15,806)
(15,973)
Tax Rate
NOPAT
(21,298)
(7,551)
1,808
Net income
(37,725)
65.54%
(22,789)
64.39%
(13,863)
-21.97%
Dividends
Dividend yield
Proceeds from repurchase of equity
90,489
10,698
BB yield
-19.16%
-5.88%
Debt
Debt current
310
178
260
Long-term debt
1,916
275
1,368
Deferred revenue
Other long-term liabilities
274
180
78
Net debt
(64,649)
(15,118)
(27,482)
Cash flow
Cash from operating activities
(38,589)
(24,422)
(21,782)
CAPEX
(307)
(491)
(387)
Cash from investing activities
(307)
(477)
32,680
Cash from financing activities
90,194
11,441
(182)
FCF
(23,698)
(9,027)
(4,346)
Balance
Cash
66,875
15,572
29,110
Long term investments
Excess cash
65,772
14,781
28,308
Stockholders' equity
81,055
28,443
40,202
Invested Capital
16,670
14,157
12,916
ROIC
22.05%
ROCE
EV
Common stock shares outstanding
3,935,911
3,248,815
3,218,794
Price
0.12
114.29%
0.06
-13.85%
0.07
-58.06%
Market cap
472,309
159.61%
181,934
-13.04%
209,222
-56.85%
EV
408,219
167,508
182,589
EBITDA
(37,789)
(22,475)
(13,325)
EV/EBITDA
Interest
49
27
33
Interest/NOPBT